Skip to main content

Blood pressure study points to more equitable care in England than America

In the USA but not in England, patients on low incomes with high blood pressure have their condition managed poorly compared with those who earn more.

A new study from my department comparing blood pressure management in the US and England found that although there is little difference between the two countries overall, the level of socioeconomic inequality is much higher in the US, with wealthier Americans more likely to meet targets for bringing their blood pressure under control than poorer patients. The study was published in the journal PLOS ONE.

High blood pressure, or hypertension, is the leading cause of ill health worldwide and affects 76 million people in the US and 16 million in the UK. It is diagnosed if someone’s blood pressure consistently measures 140/90 millimetres of mercury or higher. Doctors usually recommend lifestyle changes to control blood pressure, and may prescribe antihypertensive drugs.

The research aimed to determine whether differences between the British and American health systems influence the quality of hypertension management and disparities between socioeconomic groups, using data from national surveys.

People aged 65 and over, who have universal coverage through Medicare in the US, were considered separately from those aged 50-64, who have varying coverage under a market-based system. In England, the National Health Service offers universal health coverage with free care at the point of delivery for all ages.

In over-65s, American patients with hypertension were modestly more likely to meet clinical targets for blood pressure control than those in England. In patients aged 50-64, there was no significant difference between the countries.

However, in both age groups in the US, wealthier patients were more likely to meet targets for bringing their blood pressure under control than poorer patients. There was no disparity based on wealth or income in English patients.

Lead author Dr Andrew Dalton, now at Oxford University, said: “These findings show that for patients with high blood pressure, the English universal healthcare model provides a similar quality of care to the US market-based system, but does so much more equitably across the population.”

Dr Christopher Millett, the senior author of the study, from the School of Public Health at Imperial College London, said: “Our finding of equitable care for hypertension in England is probably due to the strong primary care system and the negligible cost of care to patients in the NHS, features lacking in the US system. The findings suggest that the US competitive market approach being introduced into the NHS may not produce the improvements in quality the government is hoping for and could reduce equity in care between poor and rich groups.”

Comments

Popular posts from this blog

Can GPs issue private prescriptions to NHS patients?

The NHS prescription charge in England is currently £8.60 per item. At this level, many commonly prescribed drugs will cost less than the prescription charge and so some NHS patients may occasionally ask if they can have a private prescription rather than an NHS prescription.

In the past, some GPs have been advised that they could issue both an NHS FP10 and a private prescription, and let the patient decide which to use. But the British Medical Association's General Practice Committee has obtained legal advice that said under the current primary care contract, GPs in England may not issue a private prescription alongside or as an alternative to an NHS FP10 prescription. In any consultation where a GP needs to issue an FP10, the concurrent issue of a private prescription would be a breach of NHS regulations.

The issuing of a private prescription in such circumstances could also be seen as an attempt to deprive the NHS of the funds it would receive from the prescription charge. Fur…

What will Brexit mean for the NHS?

On the 29 March 2017, the Prime Minister of the UK Theresa May, formally notified the European Union (EU) Council President, Donald Tusk, of the UK’s intention to leave the EU. Theresa May’s letter to Donald Tusk triggers a two-year process during which the UK will have to negotiate both the terms of its exit from EU and the arrangements that will replace those we have had for over 40 years with the other member states of the EU. The consequences of the United Kingdom’s departure from the EU (commonly referred to as ‘Brexit’) will be wide-ranging and will affect all areas of UK’s society, including the National Health Service (NHS).

For the NHS, Brexit comes at a time when it faces many other major challenges. These include severe financial pressures, rising workload, increased waiting times for both primary care and specialist services, and shortages of health professionals in many key areas (such as in general practice and in emergency departments). The NHS also faces challenges fr…

Dr Demis Hassabis, Co-Founder and CEO of DeepMind, Speaks about AI in Healthcare

On 28 September 2017, I attended the Annual Institute of Global Health Innovation Lecture: Artificial General Intelligence and Healthcare, delivered by Dr Demis Hassabis, co-founder and CEO of Google DeepMind. Artificial intelligence is the science of making machines smart argued Dr Hassabis, so how can we make it improve the healthcare sector? Dr Hassabis then went on to describe the work that DeepMind was carrying out in healthcare in areas such as organising information, deep learning to support the reporting of medical images (such as scans and pathology slides), and biomedical science. Dr Hassabis also discussed the challenges of applying techniques such as reinforcement learning in healthcare. He concluded that artificial intelligence has great scope for improving healthcare; for example, by prioritising the tasks that clinicians had to carry out and by providing decision support aids for both patients and doctors. Dr Hassabis also discussed some of the ethical issues in using …